Trial result ·
Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This analysis was done after the phase 3b JUMP trial ended. It looked at adding anemia-supporting drugs to ruxolitinib in myelofibrosis with anemia. 101 patients had hemoglobin below 12.0 g/dL. They started an ESA or danazol within 3 months. They kept it for at least 3 months. A comparison group of 1242 patients did not start these drugs. The team also checked spleen length and symptom response.
What they found
Both groups had similar starting traits. The daily ruxolitinib dose stayed above 25 mg. At week 24, response rates were close to those of the comparison group. They were also close to those of the full JUMP group of 2233 patients. Results were similar in 52 patients with hemoglobin below 10.0 g/dL. In all groups, hemoglobin rose after week 4, following an expected early dip.
What it means for patients
The authors say the results support the use of anemia-supporting drugs with ruxolitinib. They say these drugs may allow the ruxolitinib dose to stay at full strength. This is in patients with myelofibrosis and anemia.
Why it is not certain yet
This was a post hoc analysis, done after the main trial. The comparison group was not paired with the treated patients. Patients were not randomly put in groups for this question. The abstract does not give results beyond week 24.
Source
Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
PubMed · PMID 42698151We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myeloproliferative neoplasms publications